Stuart Cable is a trusted advisor to a number of world’s most innovative companies and their Boards of Directors. From emerging startups to established global brands in the technology and life sciences sectors, Mr. Cable’s visionary leadership, business acumen and unparalleled experience in M&A, corporate finance and corporate governance permit him to help the most innovative companies navigate the future.

Mr. Cable’s boundless commitment to innovation has also made him the driving force behind a number of the firm’s pioneering programs, initiatives and partnerships. Fifteen years ago he founded Goodwin's Directors Forum, the firm's annual forum designed specifically for the directors of public companies. He also founded Goodwin Labs, a pro bono program supporting life sciences startup incubators.

Most recently, Mr. Cable co-founded with his partner, Lisa Haddad, GOOD Directors, a first-of-its-kind national leadership program designed to create opportunities for next-generation, BIPOC, LGBTQ+ and women leaders to join Boards of Directors of public companies.

Mr. Cable is a fellow in the American College of Governance Counsel, a professional, educational, and honorary association of lawyers widely-recognized for their achievements in the field of corporate governance.

Areas of Practice
Domaines D’Expertise





Mr. Cable counsels boards of directors and management teams on corporate governance, mergers and acquisitions, and disclosure and securities law matters. He represents buyers, sellers and investment banks in his M&A practice, as well as the private equity and venture sources investing in such companies and investment banks serving such industries.

Mr. Cable’s innovative technology and life sciences representative clients include: Ansys, AvroBio, Aura, Cerevel, Citrix, Flagship Pioneering, Generate, Inzen, Laronde, Mirati, Moderna, PAREXEL, PTC, Repertoire Immune Medicines, Plug Power, Rubius, Shields Healthcare Solutions, Tessera Therapeutics, Valo Health, and Yumanity.

Representative Matters



M&A and Strategic Partnerships
  • Valo Health in its announced 2021 business combination with Khosla Ventures Acquisition Co. ($2.8 billion)
  • Cerevel Therapeutics in its 2021 business combination with ARYA Sciences Acquisition Corp II ($440 million)
  • Represented financial advisor in Pandion Therapeutics’ 2021 definitive sale to Merck ($1.85 billion)
  • KIND in its 2020 definitive acquisition by Mars, Incorporated ($5 billion)
  • MyoKardia in its 2020 acquisition by Bristol Myers Squibb ($13.1 billion)
  • Represented financial advisor in Immunomedics’ 2020 sale to Gilead Sciences, Inc. ($20 billion)
  • Represented financial advisor in Principia Biopharma’s 2020 acquisition by Sanofi ($3.68 billion)
  • Represented financial advisor in Forty Seven’s 2020 acquisition by Gilead Sciences ($4.9 billion)
  • AMAG Pharmaceuticals in its 2020 sale to Covis Group ($500 million)
  • Represented financial advisor in Arqule’s 2020 acquisition by Merck ($2.7 billion)
  • Spark Therapeutics in its 2019 sale to Roche ($4.4 billion)
  • Twilio in its 2019 acquisition of SendGrid ($3 billion)
  • Civitas in its 2019 acquisition by Centerbridge ($1.4 billion)
  • Keryx in its 2018 merger with Akebia ($1.3 billion)
  • Foundation Medicine in its 2015 majority sale to Roche ($1 billion) and the subsequent 2018 negotiated tender for the public stub by Roche ($2.4 billion)
  • PTC in its 2018 strategic partnership with Rockwell Automation ($1 billion)
  • PAREXEL in its 2017 sale to Pamplona ($5 billion)
  • AMRI in its 2017 sale to Carlyle and GTCR ($1.9 billion)
  • The 2016 Reverse Morris Trust merger of a division of Citrix into LogMeIn ($2 billion)
  • The 2016 private company sale of Stemcentrix to Abbvie ($5.8 billion)
  • Teva Pharmaceuticals in its 2015 acquisition of Auspex ($3.5 billion)
  • Xoom in its 2015 sale to PayPal ($1 billion)
  • Onyx Pharmaceuticals in its 2013 sale to Amgen ($10.4 billion)
  • Eloqua in its 2012 sale to Oracle ($1 billion)
Financings and Public Offerings
Special Committee Representations
Mr. Cable is also retained from time to time to represent "independent" or "special" committees of the Board of Directors in complex M&A transactions, including most recently the representation of the Special Committee of the Board of Directors of NantKwest in NantKwest’s merger with ImmunityBio (March 2021) and the Transaction Committee of Sprint in Sprint Corporation’s merger with T-Mobile US, Inc. (April 2020).

Mr. Cable serves as a member of the President's Leadership Council at Dartmouth College, as chairman emeritus of the Buckingham Browne & Nichols School and as a member of the Board of the Arthur L. Irving Institute for Energy & Society at Dartmouth College. He also served for more than a decade as a member of the Board of Fellows of Harvard Medical School.

Mr. Cable leads the firm’s pro bono efforts on behalf of Camp Harbor View, a summer enrichment program for Boston’s youth founded by Jack Connors. Mr. Cable is also a member of the Goodwin pro bono team advising the Boston Red Sox Foundation on Board and governance matters.


Mr. Cable is continually recognized for his leadership in the public M&A and corporate governance sectors, and has been included in numerous legal guides, including annual rankings in Chambers USA, U.S. News-Best Lawyers, and The Legal 500, for his expertise in the industry. His recent individual recognitions include:

  • LMG Life Sciences, Corporate Attorney of the Year in 2019;
  • Law360, Life Sciences MVP in 2017; and,
  • LMG Life Sciences, Life Sciences Transaction Attorney of the Year in 2016.

In The News









J.D., 1979
Columbia Law School

(Harlan Fiske Stone Scholar)

M.B.A., 1976
Tuck School of Business at Dartmouth
A.B., 1975
Dartmouth College

(magna cum laude)



Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique